Irene is the Director of Drug Discovery at Verge Genomics in San Francisco, CA. She has spent her career in early drug discovery in neuroscience and oncology having led multiple programs, one of which was of a novel opioid analgesic with demonstrated efficacy in Phase 3 clinical trials. At Verge Genomics, she works with biologists and computational scientists to test artificial intelligence enabled machine learning predictions at the bench to identify novel therapeutics in neurodegenerative diseases.
Safety Science Principal Medical Director
Shaun Comfort – Safety Science Principal Medical Director
Associate Director, Translational Medicine and Emerging Innovations
Leslie Cousens – Associate Director, Translational Medicine and Emerging Innovations
Leslie earned her Ph.D. in biology and medicine, with a focus on immunology, from Brown University in 1999. Her academic research experience in cellular and molecular immunology includes basic science in small animal models through translational science in cellular immunotherapy. Prior to AstraZeneca, she was leading the research and development efforts for a small biotech company in Providence, Rhode Island. Leslie joined AstraZeneca’s Emerging Innovations Unit in January 2015, where they take an entrepreneurial approach to deliver new medicines through drug repositioning by leveraging external science via the pioneering “open innovation” platform, by incubating novel technologies and by project partnering.
Savan Devani is the Founder and CEO of BioTrillion, a health technology company developing BioEngine4D to digitally detect developing diseases.
Previously, Savan spent the majority of his 15 year career in the Life Sciences industry working as a healthcare investment banker with hundreds of innovators. From Analyst through Managing Director, Savan led 40 deals, totaling $35 billion, across the drug, diagnostic, and device spectrum. Savan began his career as a little bioengineer in a big lab at Life Technologies.
Savan graduated with a B.S.E. in Bioengineering from the University of California at Berkeley and a M.S.E. in Bioengineering from the University of Pennsylvania.
A deeply personal experience later in life made Savan truly realize how much in healthcare needed to change – his mother was suddenly diagnosed with stage IVb cancer – which compelled asking “where were all the signs” and “isn’t there a better way,” which led to BioTrillion.
Associate Director Materials and Innovation
Ronald Dorenbos – Associate Director Materials and Innovation
As Associate Director of Materials & Innovation and as a member of Takeda’s Digital Strategy team for Neuroscience Ronald helps Takeda with its technology and innovation strategy, identifying technologies that can benefit Takeda’s core areas Oncology, Neuroscience and Gastroenterology. Earlier, at the Life Science division of PA Consulting, Ronald led projects for some of the world’s top 10 pharmaceutical companies that included projects around strategy, commercialization, and digital health and at his company BioFrontline he provided management, strategy and commercial advice to life sciences companies around the world. After obtaining MAs in Biotechnology and Molecular Biology and a Ph.D. in Pharmaceutical Biology he spent six years at Harvard studying Parkinson’s, Schizophrenia and the genetics of aggressive behavior before making the transition to industry. Ronald is a keen follower of applications of AI and deep learning in pharma and healthcare and is the founder of the LinkedIn group 'AI – Artificial Intelligence.'
Head of U.S. Health Informatics and Analytics
Victoria Gamerman – Head of U.S. Health Informatics and Analytics
Senior Vice President, Clinical Innovations
SAAMA TECHNOLOGIES, INC.
Amit Gulwaldi – Senior Vice President, Clinical Innovations
SAAMA TECHNOLOGIES, INC.
Analytics Executive in Residence
UNIVERSITY OF DENVER
Evon Holladay is a seasoned professional in architecting enterprise intelligence solutions and running analytics operations. She has built scalable, high-value solutions for healthcare, telecommunications, retail, and manufacturing. She is passionate about working with a broad range of stakeholders to develop a strategy and then operationalize the strategy into solutions that provide measurable value.
As the former Vice President Enterprise Intelligence for Catholic Health Initiatives (CHI), she led CHI’s Population Health Analytics and Data strategy. This included the formation of an industry-leading information management governance structure for CHI’s analytics portfolio, enterprise data warehouse, data governance and enterprise information architecture.
Currently, she is using her research skills to help provide new insight into the health-healthcare-health insurance conundrum. She is collaborating with a broad range of viewpoints — in the US and internationally — ranging from health economists, healthcare providers, health insurance, and alternative medicine. Her research is focused on the impact of healthcare spending on personal income and the changes in the health of the US population.
She also is an analytics advisory board member for DU’s Business Information and Analytics department. She regularly presents her work nationally and internationally. At DU she guest-lectures and works with her business peers to provide timely capstone project opportunities.
Director — Clinical Development Quality
Alex (Wen-Yaw) Hsieh – Director — Clinical Development Quality
Senior Manager A.I./Machine Learning Development
Kevin Hua – Senior Manager A.I./Machine Learning Development
Dr. (Kevin) Hua has 20 years of experience working in design and development of AI/Machine Learning applications in healthcare, insurance, banking, retails and manufacturing industries. He is currently a senior manager with the Digital Health Intelligence Group of Bayer, responsible for developing AI/ML applications. Prior to Bayer, he was a machine learning specialist at Deloitte Consulting and a research manager of AI at Center for Advanced Research of PwC. His work in analytics has won the Analytics Leadership Award from IU Kelley School of Business in 2014 and INFORMS Data Mining contest in 2008.
Christopher Jordan is principally responsible for all aspects of Click’s technology strategy and development, with product, design, engineering, and data science teams reporting into him. Mr. Jordan has over nine years of technology management experience and played a key role as an engineering manager at Bloomberg LP prior to joining Click. Mr. Jordan holds a BSE in Computer Engineering from the University of Michigan.
Chief Technology Officer
Theo Kornyoh – Chief Technology Officer
Director Center for Supply Chain Innovation
TEXAS CHRISTIAN UNIVERSITY
Dave Malenfant – Director Center for Supply Chain Innovation
TEXAS CHRISTIAN UNIVERSITY
M. Dave Malenfant is currently Executive Vice President of Industry Liaison and Talent Development for the BSMA (Biotech Supply Management Alliance). He also serves as Director and oversees the Advisory Board for the Center for Supply Chain Innovation at Texas Christian University. Dave is responsible for driving Industry relations in the Biotech, Biopharma Supply Chain for the BSMA. Prior to this appointment, Dave served on the Advisory Board for the BSMA from its inception. With a passion for talent development and career planning, Dave has helped both the BSMA and the Center for Supply Chain Innovation drive Young Professional career development and mentoring programs for students.
Prior to joining the BSMA and TCU, Dave spent over 30 years in a variety of industry roles. As an entrepreneur, Dave was Co-founder and President of Signature Consultants, Inc., (1973) a business, finance, and economic consulting firm that he ultimately sold in 1993. He created and operated a variety of other businesses that are still profitable in Canada today.
In 1993, Dave joined Alcon Laboratories where he steadily advanced through leadership roles such as Purchasing Manager, Materials Operation Manager, and Global Supply Chain Director before becoming the Vice President of Global Supply Chain in 2005. In this role, Dave provided strategic direction for the company’s Global Supply Chain initiatives and created global centers of excellence for Purchasing, Distribution, Transportation, Customer Service, Sales and Operations Management, Data Management, Graphic Design and Artwork Development, and Product Launches. Dave retired from Alcon in 2014.
Dave is recognized for the creative development of standardized systems and business processes, and for developing enabling technology throughout the entire supply chain. During his career, Dave has implemented over 30 different computer systems — WMS, ERP, Finite Scheduling, Product Launch, and Order Entry, among others. Dave is past Chairman of the Supply Chain Council and past member of the Executive Committee of NASSTRAC.
Given his vast knowledge of the end-to-end, integrated supply chain, Dave is a frequent speaker on Global Supply Chain Trends. He has consistently demonstrated his passion for Supply Chain management, developing talent, and the need to advance Supply Chain theory and innovation throughout a variety of industries.
Head of AI
Brian Martin – Head of AI
Associate Consultant I
Che Ngufor – Associate Consultant I
Executive Director, Center for Health Systems Innovation (CHSI)
OKLAHOMA STATE UNIVERSITY
William Paiva – Executive Director, Center for Health Systems Innovation (CHSI)
OKLAHOMA STATE UNIVERSITY
William D. Paiva, Ph.D., is Executive Director of Oklahoma State University’s Center for Health Systems Innovation (CHSI). The Center is focused on transforming rural and Native America health through the implementation of innovative care delivery and IT solutions. Within CHSI, the Institute for Predictive Medicine is applying advanced analytics to the largest health care database which includes clinical information for over 63 million patients covering 16 years.
Prior to joining Oklahoma State University, Dr. Paiva was a partner, joined Sevin Rosen Funds, a fund with over $2 billion under management, where he brought more than 20 years of venture-capital, biomedical-industry and management-consulting experience to the firm. William specialized in identifying early-stage venture opportunities at the intersection of traditional technology sectors and healthcare. He also used his healthcare expertise and network to assist Sevin Rosen portfolio companies developing applications and services for the healthcare market. Prior to Sevin Rosen, William was a partner at Chisholm Private Capital Partners, where he managed a $100 million fund focused on healthcare and IT. He also worked as a manager at the Oklahoma Life Science Fund, managing $15 million and making investments in diagnostics, services and therapeutics firms.
Before that, William served as a management consultant for the Life Sciences Industry Group at Pittiglio Rabin Todd & McGrath, later acquired by PriceWaterhouseCoopers, where he consulted with the top five pharmaceutical companies on product-development and technology-management projects. William also served as an investment banking associate at JP Morgan in New York, providing strategic and investment banking advisory services to Fortune 100 healthcare companies.
William holds a Ph.D. in molecular biology from the University of Oklahoma; an MBA from Dartmouth College’s Amos Tuck School of Business; a master’s degree in microbiology and immunology from the University of Oklahoma Health Science Center; and a B.S. in microbiology from the University of Oklahoma.
Director, Communities and Initiatives Development, Emerging Technology
IEEE STANDARDS ASSOCIATION
Maria Palombini – Director, Communities and Initiatives Development, Emerging Technology
IEEE STANDARDS ASSOCIATION
Maria is the creator, leader and advocate for the Pharma Blockchain Initiative, which seeks to bring awareness and balanced learning to the pharmaceutical community and its key stakeholders on the viable applications of blockchain within the pharmaceutical framework. The goal of the initiative is the advanced adoption of blockchain in combination with emerging technologies (ie. AI, IoT, etc) where it will lead to enhanced patient safety and care, and optimize and innovate the drug development life cycle.
In 2017, Maria joined IEEE-SA with a directive to build communities and advance initiatives to develop standards for enterprise adoption of emerging technologies. Her work includes building communities of technologists, industry executives, academic researchers and industry stakeholders to educate on the benefits and challenges of viable applications of emerging technologies while building consensus on recommendations for frameworks on technical standards and recommended guidelines for protocol and policies to enhance the outcomes of technology implementation. Her primary areas of focus include the pharma, health, supply chain, energy, and agriculture sectors. In parallel to her work in blockchain standards, she is the project lead for IEEE-SA’s newest initiative, Digital Inclusion through Trust and Agency, a critical program focused on bringing the outstanding 50% of the world’s population online while working with technologists, advocacy groups and policy leaders on developing trusted frameworks that will protect the digital persona, the right to be forgotten, and restoring dignity to digital transactions for ALL members of the global community.
In 2015, Maria left Euromoney Plc, one of the world’s leading information and event producers. She founded DisruptiveRx™, an information company that would produce written and in-person educational programs and bring pragmatic attention to breakthrough innovations that would transform life sciences and healthcare enterprise operations.
Her career started at the prestigious IEEE (Institute for Electronic and Electrical Engineers) and moved onto highly respected media companies including Penton Media, Advanstar Communications, IIR, Reed Business Information and Nielsen Business Media. She successfully led the global branding, marketing, and public relations campaign for the world’s largest mining investment networking platform, Mining Indaba™, in Cape Town, South Africa.
Maria currently holds an MBA from the Rutgers Graduate School of Business and a BA and BS from Rutgers College at Rutgers University, the State University of New Jersey. She is an accomplished leader and public speaker having presented at various industry events. You can follow her on twitter @DisruptiveRx or on LinkedIn.com/in/mpalombini.
, Ph.D., MBA
Director, Global Scientific Affairs Global Health Economics Outcomes Research and Health Policy
Jamie Partridge – Director, Global Scientific Affairs Global Health Economics Outcomes Research and Health Policy
Zeenat Patrawala – Partner Development
Offering Leader, IBM Clinical Trials Transformation Life Sciences
IBM WATSON HEALTH
Prasanna Rao – Offering Leader, IBM Clinical Trials Transformation Life Sciences
Malaikannan Sankarasubbu is the VP of AI Research in Saama Technologies. He is currently working on optimizing and accelerating clinical trials using Artificial Intelligence. He specializes in deriving insights with unstructured data like text and images. He previously was Founder and CTO for Datalog.ai creators of MyPolly, a chatbot building platform with its own Natural Language Understanding Engine where he built a community of 1,200 active developers, aka chatbot builders, around MyPolly. Malaikannan was part of the Enterprise Architecture team in Optum and Cognizant Technology Solutions. He understands Healthcare and is passionate about advancing more applications of Deep Learning in Healthcare and Life Sciences. Malaikannan loves building community; he along with few others built a community around Keras and he also created an active forum Indian Deep Learning Initiative which has over 4,500 members. Malaikannan actively shares his knowledge in Meetups and conferences and loves to blog about Artificial Intelligence at malaikannan.io.
, R.Ph., MBA, LSSMB
Director, Specialty Clinical Innovation and Program Development
Christine Sawicki – Director, Specialty Clinical Innovation and Program Development
Christine leads innovation for CVS Health’s Specialty division. Her team identifies and introduces solutions that improve patient experience, enhance clinical care, and provide cost-effective solutions to deliver the highest level of clinical care.
Ms. Sawicki has more than 25 years’ experience with CVS Health. She has also led pharmacy design and technology and pharmaceutical water system innovation and was a practicing pharmacist in the health plan, retail, hospital, and long-term care settings. Christine is a three-time CVS Health Breakthrough Award recipient for innovations and business solutions.
Ms. Sawicki received holds a B.A. in Chemistry from Assumption College where she is also adjunct faculty for MBA and Health Advocacy programs, Pharmacy Degree from MCPHSU, MBA from Anna Maria College, Lean Six Sigma Master Black Belt from Villanova University, and Pharmacoeconomic Certification from the University of South Carolina.
Justin Smith, Ph.D. leads the development of advanced analytics as Enterprise Director of Data and Analytics for Sanford Health, an organization with over 29,000 employees, 43 hospitals, and 250 clinics across nine states and three countries.
Dr. Smith leads teams, in collaboration with executive leaders, to build machine learning models that enable Sanford to better understand business drivers. Dr. Smith employs a unique skill set of strong analytical skills and thought-leadership as Sanford Health transitions from the world of advanced analytics to artificial intelligence.
Dr. Smith has published numerous articles in peer-reviewed international journals. He holds a Ph.D. in the field of Neuroscience and an M.S. and B.S. in Research Psychology.
Dr. Kelly Stanton is a bioinformatics expert and visiting scientist at Yale University, applying statistics, signal processing and mathematics to analyze DNA sequencing data since 2010. He earned his B.S. in Biomedical Engineering from the University of Texas at Austin and Ph.D. in Bioinformatics at Yale University in 2015. Kelly has published work ranging from bioinformatics applications to new mathematical techniques for general data science use. His post-doctoral work is focused on pioneering new deep learning based algorithms for unsupervised and semi-supervised learning. Currently, Kelly designs predictive analytics for clinical outcomes based on medical IOT data at Potrero Medical. He currently resides in San Francisco, CA.